Appendix 4E and 2023 Annual Report
Released
Released
Announcement PDF
30 Ju
F
R po t
2023
TQLMT
ABN 53 609 543 213
1
HITIQ Limited
Appendix 4E
ABN 53 609 543 213
Preliminary final report
Results for Announcement to the Market
for the year ended 30 June 2023
REPORTING PERIOD (item 1)
1
Report for the financial year ended:
30 June 2023
Previous corresponding period is the year months ended:
30 June 2022
2
RESULTS FOR ANNOUNCEMENT TO THE MARKET
Movement
Percentage
%
Amount
$
Increase in revenues from contracts with customers (item
2.1)
26
to
774,260
Decrease in loss from ordinary activities after tax (item
2.2)
27.49
to
(5,037,305)
Increase in loss after tax attributable to members (item
2.3)
27.49
to
(5,037,305)
a.
Dividends (item 2.4)
Franked amount
per security
%
Interim dividend
nil
n/a
Final dividend
nil
n/a
Record date for determining entitlements to
the dividend (item 2.5)
b.
Amount per
Security
₵
n/a
Brief explanation of any of the figures reported above necessary to enable the figures to be understood (item 2.6):
The Directors Report accompanying this Preliminary Financial Report contains a review of operations and commentary
on the results for the year ended 30 June 2023.
3
PRELIMINARY FINAL REPORT
a.
Statement of comprehensive income (item 3):
Refer to statement of profit or loss and other comprehensive income
b.
Statement of financial position (item 4):
Refer to statement of financial position
c.
Statement of cash flows (item 5):
Refer to statement of cash flows
d.
Statement of changes in equity (item 6):
Refer to statement of changes in equity
4
DIVIDENDS (item 7) AND RETURNS TO SHAREHOLDERS INCLUDING DISTRIBUTIONS AND BUY BACKS (item 14.2)
Nil.
a.
Details of dividend or distribution reinvestment plans in operation are described below (item 8):
Not applicable
2
HITIQ Limited
Appendix 4E
ABN 53 609 543 213
Preliminary final report
Results for Announcement to the Market
for the year ended 30 June 2023
5
RATIOS
Current
period
Previous
corresponding
period
$
$
(5,037,305)
(6,947,448)
Net assets
(46,861)
1,173,465
Less: Intangible assets (including net deferred tax balances)
(711,582)
(1,188,037)
Net tangible assets
(758,443)
(14,572)
a. Financial Information relating to 5b and 5c:
Earnings for the period attributable to owners of the parent
No.
No.
Fully paid ordinary shares
266,779,289
132,419,018
Weighted average number of ordinary shares outstanding during the year
used in calculation of basic EPS
203,462,837
132,419,018
₵
₵
b. Net tangible assets backing per share (cents):
(0.380)
(0.011)
c.E
(2.48)
(5.25)
arnings per share attributable to owners of the parent (cents) :
The Company does not report diluted earnings per share, as dilution is not
applied to annual losses generated by the Company. During the 2023
financial year the Company had 160,035,852 unissued shares under option
which are anti-dilutive.
6
DETAILS OF ENTITIES OVER WHICH CONTROL HAS BEEN GAINED OR LOST DURING THE PERIOD: (item 10)
a.
b.
Control gained over entities
Name of entities (item 10.1)
Nil
Date(s) of gain of control (item 10.2)
n/a
Loss of control of entities
Name of entities (item 10.1)
Nil
Date(s) of loss of control (item 10.2)
n/a
c. Contribution to consolidated profit (loss) from ordinary activities after tax
by the controlled entities to the date(s) in the current period when control
was gained / lost (item 10.3).
7
DETAILS OF ASSOCIATES AND JOINT VENTURE: (item
11)
Name of entities (item 11.1)
Percentage holding in each of these entities (item 11.2)
n/a
Nil
n/a
Previous
corresponding
Aggregate share of profits (losses) of these entities (item 11.3)
Period
$
Current period
$
N/A
N/A
3
HITIQ Limited
Appendix 4E
ABN 53 609 543 213
Preliminary final report
Results for Announcement to the Market
for the year ended 30 June 2023
8
ANY OTHER SIGNIFICANT INFORMATION NEEDED BY AN INVESTOR TO MAKE AN INFORMED ASSESSMENT OF
THE ENTITY’S FINANCIAL PERFORMANCE AND FINANCIAL POSITION (ITEM 12):
Refer to accompanying Annual Report
9
A COMMENTARY ON THE RESULTS FOR THE PERIOD (item 14)
Refer to attached Annual Report
10
AUDIT QUALIFICATION OR REVIEW
The financial information provided in the Appendix 4E is based on the Audited Financial Report (attached).
4
HITIQ Limited
ABN 5 6 9 54
ANNUAL
REPORT
30 JUNE 2023
ASX:HIQ
1
Letter from Non-Executive Chairman
Dear Fellow Shareholders,
On behalf of the Board of HITIQ, I am pleased to present HITIQ Limited’s 2023 Annual Report. It has
been another disappointing year in regard to HITIQ shareholder returns, with the Company’s share
price continuing its decline, exacerbated by the tax loss-selling period, as we neared June year-end.
Whilst there has been some recovery since year-end, the Board remains of the belief that the
Company is significantly undervalued given its leadership position in concussion management.
Although the Company remains cashflow negative, revenue growth continues to compound at a high
rate, despite its somewhat lumpy nature. In fact, contracted revenue growth for the 12 months to
June 2023 equated to +89%, surpassing $1m for the first time (as measured by 4C receipts).
Moreimportantly, we have continued to invest for future growth, further developing our
concussion management ecosystem and remain the clear global leader in this field, with a
growing suite of complementary products (essentially abroad, holistic offering from the one provider
- HITIQ).
This is evidenced by our high quality client base of world-leading sporting leagues. More exciting is
our plans for the next 12 months, whereby we will continue to move our product suite vertically into
community and sport feeder leagues, as well as launching our most exciting product yet, being
ConneQt, a concussion management database which will be able to record and regulate a sporting
participant’s lifetime head traumas as well as manage a professional “return-to-play” protocol.
As I wrote last year, HITIQ is a vanguard company, catering to early technology adopters, or sporting
leagues who take care of their participant stakeholders. While there remain some professional
leagues that are still paying lip service to what is becoming recognised as an increasingly serious and
well recognised issue as evidenced by the recent Australian Senate Inquiry, we will this year
increasing concentrate on bringing our product to a wider audience, with community participants
and parents become increasingly knowledgeable about monitoring the potential impact of contact
sports. Surveillance, Detection, Assessment & Diagnosis and ultimately Rehabilitation & Monitoring
remain critical pathways to better potential control of the severe degradation effects concussion can
have upon sports people worldwide.
It is why HITIQ exists, and I encourage shareholders to take a medium-term view and recognise the
vast potential of this Company. We are one of the few companies in this space, with growing
penetration and a holistic offering.
At Board level, I would like to thank my fellow directors Mike Vegar, Phil Carulli, Aidan Clarke and
Glenn Smith, as well as our Company Secretaries Peter Torre and since period-end James Barrie, for
their diligent efforts and counsel during the period.
On behalf of the Board, I would like to thank the management team and all our employees, for their
ongoing personal commitment and contributions to HITIQ. Our diligent and hardworking Board
members have also made a strong contribution. We look forward to delivering better value for all
stakeholders via further market penetration and continued revenue growth. Your Company remains
a critical participant in transforming the management and monitoring of potential concussion events.
I would also like to thank our many loyal shareholders who continue to support and believe in the
Company.
2
Financial year 2024 is shaping up to be our most significant year yet in terms of product launches
and revenue growth and we expect to deliver further positive news, aiming to re-build shareholder
value. Importantly, we aim to continue to be the leader in delivering the world’s premier concussion
management eco-system, assisting sporting participants better monitor and manage impacts
associated with sport.
Otto Buttula
Non-Executive Chairman
3
CEO Report
Dear Shareholders,
Thank you for your continued support particularly as this year, like the one before, has been one of
mixture of progress, challenges, and learnings. But know our team is working tirelessly to deliver the
next generation of concussion care technology to commercial success.
A traumatic concussion incident can happen to anyone, including any one of our children or
grandchildren. Be assured that your continued support ensures our children and grandchildren
receive the best technology possible to avoid and if needed, manage recovery from a concussion
event.
Our team has stayed committed to executing against our strategic plan. As a reminder the key
elements of the HITIQ strategy are as follows:
1.
2.
3.
4.
Expand consumer sales footprint, growing non-professional revenues;
Grow elite market revenues both domestically and internationally;
Continue product and platform extension;
Progress VR diagnostic tool towards regulatory approval/clearance.
An ever-increasing awareness in the consumer segment of the risks and impact of brain trauma via a
concussion incident is providing further primary market evidence that the strategy outlined by HITIQ
will deliver sustainable results for all stakeholders.
Furthermore, our strategy of acquiring major brands in the elite sports segment is assisting in our goal
of rolling out this critical technology to the grass roots level in the sport segment and the wider
community.
Operational and Financial Highlights
Key operational highlights during the year include:
Selected to be the exclusive provider of concussion technology at Rugby League World Cup;
A new partnership with Shock Doctor, a world leader and pioneer in sports mouth guards;
Secured a third Australian Innovation Patent;
League wide deal with the Premier League for CSX technology;
West Australian Football Commission to utilise Nexus technology;
Extension of consumer platform with announcement of new product – ConneQt;
Nexus trial with United Rugby Championship;
Signed First Commercial US collegiate customer;
Signing of Country Football WA as first customer for new product - ConneQt; and
First commercial deal into the military market.
What does all this mean? HITIQ has become one of the established brands in the concussion
assessment and care segment. Why is this important? It allows the Company to deliver on a cascade
marketing strategy whereby we can deliver scientifically validated and proven elite sports technology
to the consumer segment.
Should this strategy prove successful it will deliver muti-year recurring and high margin revenue to
HITIQ. But also deliver a social impact to the wider community which may only be measurable in
years to come when loved ones avoid a serious concussion incident because of the HITIQ product
range.
4
Outlook
We have been disappointed that opportunities which were expected to be executed in the year failed
to complete. Rest assured that we are undertaking enhancements to our sale model and
implementing operational e iciencies which we believe will accelerate the commercialisation
pathway for our technology.
We remain optimistic that our FY24 pipeline will deliver several material opportunities particularly in
the domestic market and, in the Northern Hemisphere. We will be focussed on delivery of agreed and
articulated milestones to provide confidence to our shareholders and the market that we are on the
right trajectory.
Our de-identified data collection strategy now places us as one of the major players in the brain
trauma sector. We believe this data strategy will provide a di erentiated value proposition to
corporates, pharmaceutical companies, insurers, and other aligned institutions that will drive a
strong, growing, and sustainable recurring revenue stream for the business.
Financial review
In terms of revenue growth, we have achieved:
The largest customer receipts quarter to date in Q3 of FY 22/23; $425k cash receipts (77%
of FY’22); and
E ectively doubled our top line contracted revenue and cash receipts from ~$500k to >$1m
during the year.
The statement of profit or loss and other comprehensive income shows a loss of $5,037,305 (2022:
$6,947,448) for the year. As of 30 June 2023, the Group had a cash position of $1,979,136 (2022:
$2,939,147). Operating, financing, and investing activities incurred a net cash outflow for the year of
$960,011 (2022: $6,015,983).
Capital and corporate structure
During the period, the Company undertook a $3.96m, net of transaction costs, raise via a
Renounceable rights issue.
Finally, I would like to thank our customer base who have been ambassadors for the HITIQ product
range. And further acknowledge the work of all our stakeholders including the HITIQ team and
shareholders in helping the board deliver on the promise of this Australian invented and best-ofbreed brain care technology.
Mike Vegar
Managing Director
5
HITIQ Limited
Corporate Directory
30 June 2023
Directors
Otto Buttula
Philip Carulli
Aidan Clarke
Glenn Smith
Michael Vegar
Company secretaries
Peter Torre (resigned 30 June 2023)
James Barrie (appointed 1 July 2023)
Registered office
C/o Optima Partners
Suite 3, 128 Main Street
Osbourne Park, WA, 6017
Phone: 08 6267 2200
Principal place of business
Suite1, Level 2
9-17 Raglan Street
South Melbourne, VIC, 3205
Phone: 0478 038 567
Share register
Automic Group
Level 2, 267 St Georges Tce
Perth, WA, 6000
Phone: 1300 288 664
Auditor
William Buck Audit (Vic) Pty Ltd
Level 20, 181 William Street
Melbourne VIC 3000
Solicitors
Steinepreis Paganin
Level 4, The Read Buildings
16 Milligan St
Perth, WA, 6000
K & L Gates
Level 25
525 Collins Street
Melbourne VIC 3000
Bankers
Commonwealth Bank of Australia
3 Queen Street
Fremantle, WA, 6161
Stock exchange listing
HITIQ Limited shares are listed on the Australian Securities Exchange (ASX code:
HIQ)
Website
www.hitiq.com
Patent Attorney
Forward Intellectual Property Pty Ltd
Level 2, 11 York St
Sydney, NSW, 2000
6
HITIQ Limited
Directors' Report
30 June 2023
The directors present their report, together with the financial statements, on the consolidated entity (referred to hereafter as
the 'consolidated entity') consisting of HITIQ Limited (referred to hereafter as the 'company' or 'parent entity') and the entities
it controlled at the end of, or during, the year ended 30 June 2023.
Directors
The following persons were directors of HITIQ Limited during the whole of the financial year and up to the date of this report,
unless otherwise stated:
Otto Buttula
Philip Carulli
Aidan Clarke
Glenn Smith
Michael Vegar
Principal activities
During the financial year the principal continuing activities of the consolidated entity were the development and
commercialisation of concussion management technology.
No significant change in the nature of these activities occurred during the year.
Key risks and uncertainties
HITIQ Limited is subject to both specific as well as general risks.
Sufficiency of funding
The consolidated entity doesn't have a lot of resources and will need more funds to keep working on its technology and
products, and to reach its long-term goals. Furthermore, factors such as how the economy and stock markets are doing are
beyond the control of the directors and may be a hindrance to raise capital.
Technology, manufacturing and product quality risk
The consolidated entity uses different hosting providers to keep its technology platforms and services running smoothly.
However, there's a risk that these systems could go down due to various reasons. If one of the hosting providers stops
working with the company, it could cause problems like lost revenue, damage to the company's reputation, and financial
issues.
Although the Company manufactures its products at its own premises, HITIQ currently relies on a number of external
Suppliers for key components of its technologies. There is no guarantee that these suppliers will be able to meet the cost,
reliability, volume, or lead times required for HITIQ to remain competitive in the future. These suppliers are also exposed to
the regulatory and compliance requirements faced by HITIQ. There is no guarantee that the suppliers will adequately
conform to these standards in the future. A failure to meet regulatory standards could result in enforcement actions that
could be extended to HITIQ.
Protection of intellectual property
HITIQ’s success depends, in part, on its ability to obtain, maintain and protect its intellectual property, including its patents.
Actions taken by HITIQ to protect its intellectual property may not be adequate, complete or enforceable and may not
prevent the misappropriation of its intellectual property and proprietary information or deter independent development of
similar technologies by others.
HITIQ may also suffer damage if former employees infringe its intellectual property rights or assert their moral rights. The
granting of a patent does not guarantee that HITIQ’s intellectual property is protected and that others will not develop
similar technologies that circumvents such patents.
There can be no assurance that any patents HITIQ owns, controls or licenses, whether now or in the future, will give HITIQ
commercially significant protection of its intellectual property.
Additionally, monitoring unauthorised use of HITIQ’s intellectual property rights is difficult and can be costly. HITIQ may not
be able to detect all unauthorised use of its intellectual property rights.
Changes in laws in Australia and other jurisdictions in which HITIQ operates may adversely affect HITIQ’s intellectual
property rights.
7
HITIQ Limited
Directors' Report
30 June 2023
Competition and development of intellectual property
HITIQ is in competition with other companies creating similar technologies. The Company is at risk because its rivals might
gain more customers by being aggressive in sales, marketing, or pricing. There's also a chance HITIQ might not react as
fast as competitors to changes in the market or customer needs. Additionally, new companies entering the industry could
make products that compete with HITIQ's offerings.
Information on directors
The names, qualifications, experience and special responsibilities of each person who has been a director during the year
and to the date of this report are:
Name:
Title:
Experience and expertise:
Michael Vegar
Managing Director and Chief Executive Officer
Mr Vegar is a co-founder and Managing Director of HITIQ.
He has been responsible for creating and executing HITIQ’s strategic plan, fundraising
& developing the product’s vision, as well as growing the HITIQ team from conception
to now a team of 25 people. Mr Vegar has extensive experience in the sporting industry
across a variety of roles with more than 13 years of domain knowledge. He holds a
Bachelor’s Degree of Commerce and a Master’s Degree of Exercise Science.
Before co-founding HITIQ, Mike operated a sport science consultancy firm advising
various professional and semi-professional sporting programs from 2008 – 2017,
including working in the High-Performance Unit at the Australian Institute of Sport with
the Australian Men’s Hockey program. In that role, Mr Vegar was responsible for
managing the injury rehabilitation and physical preparation programming. In 2012, Mr
Vegar also co-founded Game Guardian, a leading Australian manufacturer of mouth
guards and sports protection goods, which he exited in 2020.
Other current directorships:
Former directorships (last 3 years): Interests in shares:
12,437,499
Interests in options:
11,333,333
8
HITIQ Limited
Directors' Report
30 June 2023
Name:
Title:
Experience and expertise:
Otto Buttula
Non-Executive Chair
Mr Buttula has had extensive experience and success in investment research, funds
management and information/biotechnology, holding directorships in a number of
public companies.
Mr Buttula’s executive experience includes as a co-founder, CEO and Managing
Director of IWL Ltd, an online financial services company that listed on the ASX in 1999.
Growing from a market capitalisation of $48 million at listing, it was taken over in 2007
by Commonwealth Bank of Australia (ASX: CBA) for $373 million.
Mr Buttula also founded and was Managing Director of Investors Mutual, prior to which
he was a co-founder and director of Lonsdale Securities Ltd. Following his completion
of executive duties, Mr Buttula was Non-Executive Chairman of platform and
stockbroking provider Investorfirst Ltd and led the acquisition of HUB24 Ltd (ASX:
HUB).
More recently, he served on the Board as a non-executive director and Head of Audit
& Risk at Imugene Ltd (ASX: IMU) between 2014 and 2016. Currently, Mr Buttula is
also Non-Executive Chairman of Rhythm Biosciences Ltd (ASX: RHY), a company
positioning itself to be a global leader in the mass market, early detection of colorectal
cancer, via a simple blood test and a Non-Executive Director of Oncosil Medical Ltd
(ASX: OSL), a commercial brachytherapy provider specialising in pancreatic cancer.
Mr Buttula holds a Bachelor of Economics from Monash University, a Graduate
Diploma of Applied Finance & Investment and is a Fellow of the Australian Institute of
Company Directors.
Other current directorships:
Oncosil Medical Ltd - appointed 20 July 2021 (retired 31 August 2023)
Rhythm Biosciences Limited - appointed 28 October 2019
Former directorships (last 3 years): Interests in shares:
13,185,505
Interests in options:
8,407,488
Name:
Title:Experience and expertise:
Philip Carulli
Non-Executive Director
Philip Carulli is a Chartered Accountant and managing director of Optima Financial
Group Pty Ltd where he provides financial, taxation and corporate advisory services to
a diverse range of businesses. Over the past 25 years Mr Carulli has owned, managed
and consulted to companies in professional services, construction, technology,
medical, and industrial sectors to name a few.
He holds a Bachelor of Business, is a registered SMSF auditor,holds a Certificate of
Public Practice and is a member of the Institute of Company Directors. Philip has
been working with the company since incorporation in the capacity of financial
controller and former company secretary.
Other current directorships:
Former directorships (last 3 years): Interests in shares:
4,219,419
Interests in options:
2,507,335
9
HITIQ Limited
Directors' Report
30 June 2023
Name:
Title:
Experience and expertise:
Glenn Smith
Non-Executive Director
Glenn Smith is a seasoned “C-level” executive, strategy consultant, and venture
capitalist. Throughout his career, Glenn has excelled in fostering customer-centric
enterprises across various growth phases, spanning both publicly listed and private
companies.
Glenn is also a founding partner and head of the investment committee at Aruma
Capital, an Australian venture capital firm dedicated to funding transformative
technologies that enhance societal well-being. Glenn's educational background
includes an MBA from the University of Western Australia, an Undergraduate Degree
in Arts/Economics, and a Graduate Degree in Viticulture and Oenology.
Other current directorships:
Former directorships (last 3 years): Tali Digital Limited - 10 May 2018 to 31 March 2022
Interests in shares:
552,500
Interests in options:
640,000
Name:
Title:
Experience and expertise:
Aidan Clarke
Non-Executive Director
Mr Clarke is an experienced entrepreneur with close to 15 years’ experience building
and growing global brands within the sporting industry.
Having co-founded sporting brand 2XU, Mr Clarke was an Executive Director
responsible for the Sales & Marketing functions of the company. Equipping multiple
World and Olympic champions in almost every code, whilst building a global distribution
network. 2XU supplied the US Navy Seals, majority of NFL teams, and 29 of the 30
NBA teams. Mr Clarke led 2XU commercialisation efforts into numerous elite sport
relationships, such as a long serving AIS R&D agreement and signing multiple
exclusive partnerships across high performance teams and institutions throughout the
world. 2XU was partially acquired by the LVMH capital arm L-Capital for a $200m
valuation in 2014, with Mr Clarke fully exiting his shareholding in 2018.
Mr Clarke has a BA/Bcomm from Auckland University, and through experience and
track record brings a strong demand generation lens and skillset to HITIQ.
Other current directorships:
Former directorships (last 3 years): Interests in shares:
775,000
Interests in options:
700,000
'Other current directorships' quoted above are current directorships for listed entities only and excludes directorships of all
other types of entities, unless otherwise stated.
'Former directorships (last 3 years)' quoted above are directorships held in the last 3 years for listed entities only and excludes
directorships of all other types of entities, unless otherwise stated.
Company Secretary
James Barrie
James Barrie is a professional Director and Company Secretary and provides HIQ with a range of commercially focused
professional services and knowledge, including governance, share registry and employee equity plans, stakeholder relations
support and virtual shareholder meetings.
Mr Barrie (B.Bus, DiplInvRel, CPA, GAICD) is currently company secretary of ASX-listed IOUpay Limited, Global Health
Limited, Jupiter Energy Limited, InhaleRx Limited, TTA Holdings Limited and Boadicea Resources Limited, where he is also
a Non-Executive Director. Mr Barrie is also a Non-Executive Director and company secretary of NSX-listed A2A GN Limited
and Phoenician International Limited as well as several unlisted private and pre-IPO companies.
10
HITIQ Limited
Directors' Report
30 June 2023
Dividends
There were no dividends paid, recommended or declared during the current or previous financial year.
Review of operations
The loss for the consolidated entity after providing for income tax amounted to $5,037,305 (30 June 2022: $6,947,448).
The Chairman’s Letter and Chief Executive Officer’s Report contain a review of operations.
The loss of the company amounted to $5,037,305 (2022: $6,947,448 loss). The major items of expenditure include Research
and Testing $854,693 (2022: $1,727,535), Share-based payments reversed expense $209,704 (2022: $237,868 expense)
and Employee Benefits Expense $4,794,485 (2022: $4,287,450).
Significant changes in the state of affairs
During the year the consolidated entity signed several deals across multiple target sectors including:
·
·
·
·
Signed first commercial US Collegiate customer – Mercer University
Signing of Country Football Western Australia as first customer for a new product – ConneQt
Secured commercial agreements with Deakin University, Monash University and University of Canterbury for research
Significant progress with the CoVR Virtual Reality pre-clinical program
A renounceable rights offer was completed in December 2022 raising $3.9 million.
Matters subsequent to the end of the financial year
No matter or circumstance has arisen since 30 June 2023 that has significantly affected, or may significantly affect the
consolidated entity's operations, the results of those operations, or the consolidated entity's state of affairs in future financial
years.
Likely developments and expected results of operations
Information on likely developments in the operations of the consolidated entity and the expected results of operations have
not been included in this report because the directors believe it would be likely to result in unreasonable prejudice to the
consolidated entity.
Meetings of directors
The number of meetings of the company's Board of Directors ('the Board') held during the year ended 30 June 2023, and
the number of meetings attended by each director were:
Full Board
Attended
Held
Michael Vegar
Otto Buttula
Philip Carulli
Glenn Smith
Aidan Clarke
3
3
3
3
3
3
3
3
3
3
Held: represents the number of meetings held during the time the director held office.
11
HITIQ Limited
Directors' Report
30 June 2023
Shares under option
Unissued ordinary shares of HITIQ Limited under option at the date of this report are as follows:
Grant date
Expiry date
23/01/2019
16/03/2020
18/12/2020
19/03/2021
19/03/2021
19/03/2021
19/03/2021
1/06/2021
14/07/2021
10/11/2021
22/12/2022
10/12/2023
18/12/2023
18/12/2023
17/12/2023
19/03/2024
25/03/2024
25/03/2025
18/12/2023
31/07/2024
10/11/2024
16/12/2023
Exercise
price
$0.20
$0.30
$0.20
$0.20
$0.30
$0.30
$0.30
$0.30
$0.30
$0.30
$0.04
Number
under option
3,000,000
1,333,334
2,000,000
599,999
599,999
4,500,000
1,500,000
6,000,000
4,642,250
1,500,000
134,360,270
160,035,852
No person entitled to exercise the options had or has any right by virtue of the option to participate in any share issue of the
company or of any other body corporate.
During the year, 2,500,000 advisor options expired on 15 November 2022 with strike price of $0.30 (granted 15 November
2019).
Shares issued on the exercise of options
There were no ordinary shares of HITIQ Limited issued on the exercise of options during the year ended 30 June 2023 and
up to the date of this report.
Remuneration report (audited)
The remuneration report details the key management personnel remuneration arrangements for the consolidated entity, in
accordance with the requirements of the Corporations Act 2001 and its Regulations.
Key management personnel are those persons having authority and responsibility for planning, directing and controlling the
activities of the entity, directly or indirectly, including all directors.
Key Management Personnel
The following changes are noted to Key Management Personnel for the year ended 30 Jun
Share your feedback
Discover